Close Window

Digital Look Email A Friend

RBC Capital labels news on Gilead Science's Remdesivir 'promising on the surface'

Published by Alexander Bueso on 17th April 2020

(Sharecast News) - Analysts at RBC Capital sounded a positive note on reports published overnight regarding the results of a phase III clinical trial at a Chicago hospital for Gilead Science's Remdesivir drug for treating Covid-19.

URL: http://www.digitallook.com/dl/news/story/30544550/...

Email this article to your friends
NOTE: These email addresses will be used to email the information on your behalf and will not be collected by Digital Look for any marketing purposes.